Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase-facilitated breast cancer migration

2008 ◽  
Vol 103 (5) ◽  
pp. 1369-1378 ◽  
Author(s):  
Lynne-Marie Postovit ◽  
Daniel E. Abbott ◽  
Stacey L. Payne ◽  
William W. Wheaton ◽  
Naira V. Margaryan ◽  
...  
2006 ◽  
Vol 66 (S 01) ◽  
Author(s):  
JT Erler ◽  
N Dornhöfer ◽  
S Jeffrey ◽  
A Giaccia
Keyword(s):  

Antioxidants ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 312
Author(s):  
Sandra Ferreira ◽  
Nuno Saraiva ◽  
Patrícia Rijo ◽  
Ana S. Fernandes

LOX (lysyl oxidase) and lysyl oxidase like-1–4 (LOXL 1–4) are amine oxidases, which catalyze cross-linking reactions of elastin and collagen in the connective tissue. These amine oxidases also allow the cross-link of collagen and elastin in the extracellular matrix of tumors, facilitating the process of cell migration and the formation of metastases. LOXL2 is of particular interest in cancer biology as it is highly expressed in some tumors. This protein also promotes oncogenic transformation and affects the proliferation of breast cancer cells. LOX and LOXL2 inhibition have thus been suggested as a promising strategy to prevent metastasis and invasion of breast cancer. BAPN (β-aminopropionitrile) was the first compound described as a LOX inhibitor and was obtained from a natural source. However, novel synthetic compounds that act as LOX/LOXL2 selective inhibitors or as dual LOX/LOX-L inhibitors have been recently developed. In this review, we describe LOX enzymes and their role in promoting cancer development and metastases, with a special focus on LOXL2 and breast cancer progression. Moreover, the recent advances in the development of LOXL2 inhibitors are also addressed. Overall, this work contextualizes and explores the importance of LOXL2 inhibition as a promising novel complementary and effective therapeutic approach for breast cancer treatment.


Marine Drugs ◽  
2012 ◽  
Vol 10 (12) ◽  
pp. 2492-2508 ◽  
Author(s):  
Lamiaa Shaala ◽  
Diaa Youssef ◽  
Mansour Sulaiman ◽  
Fathy Behery ◽  
Ahmed Foudah ◽  
...  

2020 ◽  
Vol 22 (8) ◽  
Author(s):  
Wei‐yan Qin ◽  
Shi‐chun Feng ◽  
Yong‐qiang Sun ◽  
Guo‐qin Jiang

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3289
Author(s):  
Mi-Jeong Kim ◽  
Yoon Min ◽  
Juhee Son ◽  
Ji Young Kim ◽  
Ji Su Lee ◽  
...  

TRAF6-BECN1 signaling axis is critical for autophagy induction and functionally implicated in cancer progression. Here, we report that AMP-activated protein kinase alpha 1 (AMPKα1, PRKAA1) is positively involved in autophagy induction and cancer progression by regulating TRAF6-BECN1 signaling axis. Mechanistically, AMPKα1 interacted with TRAF6 and BECN1. It also enhanced ubiquitination of BECN1 and autophagy induction. AMPKα1-knockout (AMPKα1KO) HEK293T or AMPKα1-knockdown (AMPKα1KD) THP-1 cells showed impaired autophagy induced by serum starvation or TLR4 (Toll-like receptor 4) stimulation. Additionally, AMPKα1KD THP-1 cells showed decreases of autophagy-related and autophagosome-related genes induced by TLR4. AMPKα1KO A549 cells exhibited attenuation of cancer migration and invasion induced by TLR4. Moreover, primary non-small cell lung cancers (NSCLCs, n = 6) with low AMPKαl levels showed markedly decreased expression of genes related to autophagy, cell migration and adhesion/metastasis, inflammation, and TLRs whereas these genes were significantly upregulated in NSCLCs (n = 5) with high AMPKαl levels. Consistently, attenuation of cancer migration and invasion could be observed in AMPKα1KO MDA-MB-231 and AMPKα1KO MCF-7 human breast cancer cells. These results suggest that AMPKα1 plays a pivotal role in cancer progression by regulating the TRAF6-BECN1 signaling axis for autophagy induction.


FEBS Journal ◽  
2013 ◽  
Vol 280 (14) ◽  
pp. 3340-3353 ◽  
Author(s):  
Dongsheng Wang ◽  
Dan Liu ◽  
Jing Gao ◽  
Min Liu ◽  
Shilian Liu ◽  
...  

2018 ◽  
Vol 119 (7) ◽  
pp. 5665-5675 ◽  
Author(s):  
Yu‐Heng V. Ma ◽  
Candy Lam ◽  
Shreyash Dalmia ◽  
Peter Gao ◽  
Jacob Young ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document